Zoledronic acid for Paget's disease of bone.
Paget's disease of bone is a common skeletal disorder that often results in significant pain and disability. A number of bisphosphonates are currently available for treatment, however normalization of biochemical markers of bone turnover (the goal of treatment of Paget's disease) is rarely accomplished with currently available medications due to difficulty with administration, poor long-term adherence and possibly resistance to individual bisphosphonates. This review will focus on zoledronic acid, a potent intravenous bisphosphonate that appears to result in a higher percentage of patients with long-term normalization of markers of bone turnover than previously available drugs, thereby improving quality of life in patients with Paget's disease of bone.
Maricic
Michael
M
Catalina Pointe Clinical Research, Inc., Tucson, Arizona 85704, USA. mikemaricic@msn.com
D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use*; D007275:Injections, Intravenous; D010001:Osteitis Deformans / Q000188:drug therapy*; D011788:Quality of Life; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid